HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Prolonged survival following palliative renal tumor embolization by capillary occlusion.

AbstractNine patients with renal cell carcinoma and severe hematuria were palliatively treated with a new type of angioocclusion: the concept of capillary embolization. The so-called occlusion gel Ethibloc was used as embolizing agent. Each patient was followed up until death or for at least 4 years. All patients had a stage T3 or T4 tumor, 3 patients had metastases to multiple organs, 3 had lung metastases, and 3 were free of metastatic disease. In all cases, very high volumes (14-40 ml) of the embolizing agent were necessary to achieve total occlusion of the entire arterial compartment. Patients without metastatic disease had a mean survival time of 6 years and 4 months, all of them without signs of malignant disease. Patients with metastases had a mean survival time of 3 years. Compared with the natural history of renal cell carcinoma treated otherwise, this represents a substantial prolongation of survival time. Contrary to other angioocclusive treatment modalities, the concept of capillary occlusion with Ethibloc seems to achieve total tumor destruction.
AuthorsG W Kauffmann, G M Richter, R Rohrbach, W Wenz (Affiliation: Department of Diagnostic Radiology, University of Freiburg, Germany.)
JournalCardiovascular and interventional radiology (Cardiovasc Intervent Radiol) 1989 Jan-Feb Vol. 12 Issue 1 Pg. 22-8 ISSN: 0174-1551 [Print] UNITED STATES
PMID2496923 (Publication Type: Journal Article)
Chemical References
  • Drug Combinations
  • Fatty Acids
  • Propylene Glycols
  • Proteins
  • Diatrizoate
  • Zein
  • alcoholic prolamine solution
Topics
  • Capillaries
  • Carcinoma, Renal Cell (mortality, radiography, therapy)
  • Diatrizoate
  • Drug Combinations
  • Embolization, Therapeutic (methods)
  • Fatty Acids
  • Humans
  • Kidney (radiography)
  • Kidney Neoplasms (mortality, radiography, therapy)
  • Prognosis
  • Propylene Glycols
  • Proteins (therapeutic use)
  • Tomography, X-Ray Computed
  • Zein

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD